Relate genetic changes to mood
- Trial ID
- NCT05518617
- Official Title
- Molecular and Functional Imaging of Parkinson's Pathology in SNCA, Parkin and PINK1 Mutation Carriers
- Goal
- Relate genetic changes to mood
- Status
- RECRUITING
- Sponsor
- University of Exeter
- Study Type
- OBSERVATIONAL
- Enrollment
- 45 participants
- Conditions
- Parkinson Disease, Nervous System Disorder, Neurodegenerative Diseases, Neurodegenerative Disease, Hereditary, Parkinson's
- Interventions
- Positron Emission Tomography (PET) scan using DASB tracer
Plain-Language Summary
They want to map brain changes tied to hereditary Parkinson's genes SNCA, Parkin, and PINK1, to learn how these mutations affect non-dopaminergic systems that can drive symptoms like mood, sleep, and thinking. Participants have a PET scan with the DASB tracer, which binds the serotonin transporter so researchers can measure serotonergic nerve terminal health; the protocol also ties those images to MRI, dopamine SPECT, and spinal fluid measures, and it is observational so it does not change your Parkinson's medications. The study is looking for adults 25 to 80 who carry those mutations (or matched controls) who can tolerate PET and MRI and a lumbar puncture, are not taking serotonergic drugs like SSRIs, and do not have dementia, MRI contraindications, or bleeding risks.
Locations
- University Of Exeter, Exeter, Devon, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Positron Emission Tomography (PET) scan using DASB tracer. They want to map brain changes tied to hereditary Parkinson's genes SNCA, Parkin, and PINK1, to learn how these mutations affect non-dopaminergic systems that can drive symptoms like mood, sleep, and thinking. Participants have a PET scan with the DASB tracer, which binds the serotonin transporter so researchers can measure serotonergic nerve terminal health; the protocol also ties those images to MRI, dopamine SPECT, and spinal fluid measures, and it is observational so it does not change your Parkinson's medications. The study is looking for adults 25 to 80 who carry those mutations (or matched controls) who can tolerate PET and MRI and a lumbar puncture, are not taking serotonergic drugs like SSRIs, and do not have dementia, MRI contraindications, or bleeding risks.
- Who can participate?
- Participants must be between 25 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years.